| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 14, 2026 | OCD Flares Now Predictable Hours Ahead: Low Confidence Is Warning Signal | By Brandi Henkel
Published: Aug 14 2026, 10:14 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Nov 6, 2025 | Afraid of needles? Tips to ease your anxiety whether you’re drawing blood, getting an injection or doing Botox | Listen
9 min
New: You can now listen to articles.
This audio is generated by an AI tool.
No one likes needles. But there are times when they do get under your skin, quite literally, like during vaccination, having your blood drawn for a hea... |
| May 21, 2024 | Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease | SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| Mar 7, 2024 | Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 | ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| Feb 20, 2024 | Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA | ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| Sep 5, 2023 | I was in the hospital trying to avoid going into labor when I met 2 women going through the same. Now we, and our kids, are close friends. | Parenting I was in the hospital trying to avoid going into labor when I met 2 women going through the same. Now we, and our kids, are close friends.
Essay by Alexis Jones
2023-09-05T16:57:11Z
Share icon An curved arrow pointing right.
Share... |
| Jul 15, 2023 | Avoiding sports or any physical activity because you think you’re clumsy? Here's how to fix that | Carmen Chavez spent much of her life avoiding sports. Her aversion, she said, stemmed from the embarrassment of middle school gym class. As more athletic girls slammed volleyballs across the net, she worried about tripping or being hit by a... |
| Jun 10, 2023 | 12 skin bumps that look like pimples but aren't | Health 12 skin bumps that look like pimples but aren't
Sophia Mitrokostas
2023-06-10T12:48:07Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. It indicates the ability to send an... |
| May 11, 2023 | PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE | KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ -- In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, ... |
| May 8, 2023 | Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease | ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| Feb 15, 2023 | Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy | ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| Nov 16, 2022 | After decades of setbacks, scientists make strides toward the holy grail of male birth control | The headlines spelled the end of a short-lived scientific hope: “Male birth control study nixed after men can’t handle side effects women face daily,” USA Today announced. “Men Back Out of Male Birth Control Study Because They Couldn’t Hand... |
| Oct 7, 2022 | This Common Antiobiotic Causes Permanent Hearing Loss: Scientists Explain Why | Joaquin Victor Tacla, Tech Times 07 October 2022, 03:10 am
In order to better understand why an antibiotic causes human hair cell death and permanent hearing loss, scientists at Indiana University School of Medicine are experimenting with n... |
| Aug 18, 2022 | Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) | SAN FRANCISCO and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| Mar 28, 2022 | NUS wearable tech spinoff gets $808k seed funding | InvestmentsNewsStartups
Roehl Niño Bautista · 28 Mar 2022 · 1 min readNUS wearable tech spinoff gets $808k seed funding
Singapore-based Microtube Technologies, a wearable sensing tech firm, has raised S$1.1 million (US$808,523) in a seed ro... |
| Mar 21, 2022 | The Breen bill to protect health providers is well-intentioned. But it won’t stop burnout | Both the Senate and the House of Representatives passed a bill to “improve the mental and behavioral health among health care providers” that President Biden signed on Friday. As an emergency medicine physician who worked through the darkes... |
| Jul 26, 2021 | Beckman Coulter to Distribute BNP Cardiac Assay to Customers | - Beckman Coulter to take over distribution to customers of a B-type Natriuretic Peptide (BNP) assay, a marker of congestive heart failure on the company's immunoassay platforms
- This BNP assay for Beckman Coulter immunoassay analyzers, cu... |
| Dec 31, 2020 | Yeast infections aren’t contagious — here’s what causes them and how to avoid getting one | Yeast infections are rarely contagious, but they can cause discomfort during sex. Martin Dimitrov/ Getty Images
Yeast infections are rarely contagious and are commonly caused by an overgrowth of yeast.
Though they aren’t normally contagious... |
| Dec 5, 2020 | 7 medically-studied benefits of olive oil and why you should use it instead of butter | Olive oil contains cancer preventing antioxidants and is a healthy source of fat. Westend61/ Getty Images
Olive oil is a type of fat that contains antioxidant properties which can help prevent the onset of health issues like liver disease, ... |
| Dec 5, 2020 | 5 major causes of pneumonia and how you can prevent it | You can get pneumonia through bacterial, fungal, or viral infections.
You can also get aspiration pneumonia, which is when you inhale food, or hospital-acquired pneumonia.
To prevent pneumonia, get the flu shot, wash your hands, and stop sm... |
| Nov 23, 2020 | De-Caf Joe And The Trump D.T.’s | Former Secretary of State John Kerry is back -- as President-elect Joe Biden's newly announced ... [+] climate czar. (Photo: Win McNamee/Getty Images)Getty Images |
| Oct 6, 2020 | Woman, 25, Discovers ‘Migraines’ Caused by Tapeworm Larvae in her Brain | Doctors at an Australian hospital found tapeworm larvae in the brain of a 25-year-old woman who claimed to have been suffering from a week-long headache.
The condition, known as neurocysticercosis, occurs when a person accidentally ingests ... |
| Aug 3, 2018 | How is Stanford Medicine’s Chief Wellness Officer seeking to reduce physician burnout? (Q&A) | He lives in Portola Valley, Calif., with his wife, a nurse, who works part-time, and their four children, ages 4 to 13.
Dr. Tait Shanafelt (Julie Greicius/Stanford School of Medicine)
Shanafelt’s goal is to address the systemic problems in ... |
| Feb 15, 2018 | Collective action needed to stem burnout and restore clinician well-being and resilience | Every day, as people from all walks of life deal with burnout, they often turn to health care professionals for help. Yet the very people who dedicate their lives to keeping others healthy are the ones increasingly suffering from burnout. M... |
| Dec 22, 2016 | Aurinia rallies $25M for lupus nephritis drug | Back in October, Aurinia’s stock surged 10 percent in a matter of minutes, based on speculation that it would soon be acquired. Nothing substantial has been reported since and the company now has a clear financial path to get its lead drug ... |
| Feb 2, 2016 | Startup’s drug could prevent antibiotic-related hearing loss | Oricula Therapeutics’ aim is to protect the inner ear from damage caused by antibiotic use. In animal models, Oricula says its drug protects the delicate hair cells within the ear from antibiotic-related death.
The company just received a $... |
| Dec 3, 2015 | True North, Following the Alexion Rare Disease Playbook, Nabs $40M | Alexion Pharmaceuticals became successful by developing treatments for ultra-rare diseases, the kind hardly anybody has ever heard of. |
| Dec 3, 2015 | True North Therapeutics gets $40M new approach to autoimmune disease | True North is developing antibody drugs that work by inhibiting the complement system to prevent the generation of inflammatory mediators and phagocytic markers. The idea here is to restore immune function so that it doesn’t turn on itself ... |
| Apr 17, 2015 | A topical way to treat migraines with NSAIDs – and cut down on all those GI bleeds | CEO Crist Frangakis explained that Achelios’s drug isn’t meant to replace the current best-in-show migraine therapy, a class of drugs called triptans, but rather to complement them. Triptans cause vasoconstriction and can’t be used in folks... |
| Apr 1, 2015 | Bullet Biotechnology using the cancer vaccine approach to target B cell lymphomas | The underlying technology was developed by Stanford University lymphoma researcher Ronald Levy, in collaboration with Stanford chemical engineering professor Jim Swartz. It targets the idiotype protein
There are a number of therapies for B ... |
| Mar 31, 2015 | Catabasis raising $20.4M; modulates multiple disease pathways for Duchenne muscular dystrophy, ALS | The MIT Technology Review wrote up a nice explainer of Catabasis’ technology two years ago:
Catabasis has found a way around the challenge of identifying a single active molecule that can hit multiple pathways effectively: using a chemical ... |
| Feb 14, 2015 | Arcturus emerging as a strong player in RNA therapeutics space | The company’s data has advanced to show that this siRNA approach not only works in primates, but has demonstrated longevity in its efficacy. Here’s how Payne describes how it works:
“Imagine a spigot spinning off mutated proteins it’s not s... |
| Dec 19, 2014 | GeneSegues gets gov’t contract to develop a topical vaccine for Venezuelan encephalitis | GeneSegues develops capsules for drug delivery that are smaller than 50 nanometers, which it says increases the amount of RNAi transfer into cancer cells – the company’s primary focus. All of its work is still in the research and preclinica... |
| Dec 11, 2014 | Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication | Here’s Knopp’s pipeline:
The NIH’s National Institute of Allergy and Infectious Diseases is working with Knopp to conduct a clinical trial of dexpramipexole in hypereosinophilic syndrome, or HES, which causes multiple organ damage.
Dexprami... |
| Nov 17, 2014 | Allena Pharma’s kidney stone-preventing enzyme attracts $25M | The company was founded in 2011, with a $15 million Series A cash infusion led by Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. This current round has seven investors.
The key indication here is hyperoxaluria – a po... |
| Jun 27, 2014 | Pediatric telemedicine could help screen preemies for eye disease, study finds | Here’s a description of the study, funded by the National Eye Institute — a division of the National Institutes of Health:
“The telemedicine strategy consisted of electronically sending photos of babies’ eyes to a distant image-reading cent... |
| Jun 4, 2014 | Drug developer with kidney disease treatment raises $13M ahead of IND filing | JAFCO Life Science Investment led the Series B round and current investors also took part. Among its investors are Scientific Health Development, Wistar Morris Foundation and UpStart.
Its drug, CXA-10, will be used in an IV form to treat ac... |
| Mar 26, 2014 | Rinse-and-spit test kit company gets $2.3M to develop an early oral cancer screening | The company is developing a low-cost kit for assessing a person’s risk of oral cancer before any lesions appear in the mouth. The kit comprises a teaspoon of saline solution, a collection cup and a testing strip. A person swishes the soluti... |
| Dec 19, 2013 | We've seen the future of translational medicine ... | ... and it's disruptive
A team of 110 researchers and clinicians, in therapeutics, diagnostics, devices and digital health in 25 teams at UCSF, has just shown us the future of translational medicine. It’s Lean, it’s fast, it works and it’s ... |
| Oct 3, 2013 | Docs on new concussion sensors, apps: They help but don’t solve key issues with diagnosis | Handheld diagnostic devices. Blood tests. Helmet sensors. Apps that evaluate everything from balance to speech patterns.
They’re all efforts being put forth by companies looking to cash in on the need for more sophisticated and less subject... |
| Mar 13, 2013 | Stem cell company Athersys expects more R&D spending, potential partnerships in 2013 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Feb 18, 2013 | Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | According to a statement from the company, the funding came from Santen Inc., the California-based subsidiary of Santen Pharmaceuticals Co., Ltd in Japan, and other investors including Mountain Group Capital, Hatteras Venture Partners, Geor... |
| Jan 9, 2013 | Cardiology-focused startup improving FFR emerges in Cleveland with $250K investment | Pollman declined to go into too much detail about the specifics behind the guide wire that his new startup is developing, saying only that it takes advantage of technological advances in other industries.
“The challenge with current product... |
| Dec 13, 2012 | Hospitals see fewer birth traumas and liability claims under perinatal safety initiative | The aftermath is expensive too. In a 2012 survey of more than 9,000 obstetricians and gynecologists, more than 2,500 liability claims were reported in the obstetrics field. The average payment for the most commonly reported claim, a neurolo... |
| Nov 27, 2012 | How to engineer a social media attack on a hospital system | Since that initial announcement, both sides have given in somewhat. The hospital system extended the deadline to next Monday and 82 people got the shot or provided a reasonable excuse as to why they can’t or won’t.
The interesting part of t... |
| Nov 23, 2012 | Colon cancer prevention drug maker seeking $5 million ahead of pivotal trials | In early clinical trials, the drug combination reduced recurrence of colon polyps most commonly associated with cancer by 92 percent, the company says.
CPP was founded in 2009 by cancer prevention researchers Dr. Frank Meyskens and Dr. Gene... |
| Nov 9, 2012 | Supported by an $86 million round, first bio-artificial liver moves toward pivotal trials | Called Elad, the device has survived two companies that went bankrupt after spending $65 million developing it, according to Forbes.
In September, Vital announced closing the first tranche of a $76 million round of financing led by existing... |
| Nov 6, 2012 | Where are they now? A look at Cleveland Clinic’s “top medical innovations” of the past | A look at some of the Clinic’s choices from years past confirms that. Here are a few examples of technologies that have – and have not – lived up to their hype over the past five years”
Last year’s top innovation was catheter-based renal de... |
| Sep 13, 2012 | Hepatitis drug developer nears completion of $5 million round | Solution/product: Eiger develops treatments for hepatitis. According to its website, it has two hepatitis delta virus drug candidates (EBP921 and EBP994) in phase 2 development as well as a hepatitis C drug.
Infection with hepatitis D occur... |
| Sep 12, 2012 | Sophono raises $7M series B, rolls out new features of bone conduction hearing device | Location: Boulder, Colorado.
Solution/product: The Alpha 1 is a U.S. Food and Drug Administration-cleared hearing device for patients with conductive hearing loss, mixed hearing loss and single-ear deafness. Two models of the device are ava... |
| Sep 5, 2012 | Celiac disease immunotherapy that would replace a gluten-free diet begins clinical trials | In these patients, the body’s immune response to gluten affects the process of the small intestine and can inhibit the absorption of nutrients into the body and can potentially cause a host of deficiency complications. No medicines are avai... |
| Aug 30, 2012 | Vascular disease biopharma Aerpio nabs $27M for trials of diabetic macular edema drug | Aerpio will use the funds to proceed with a phase 1b/2a safety and efficacy study of AKB-9778 later this year and development of its inflammatory bowel disease drug. The funds should also carry the DME drug through a large phase 2 trial, th... |
| Aug 7, 2012 | Subsidiary of Depuy Synthes receives FDA approval for implantable device that treats spasticity | The MedStream Programmable Infusion System, which is implanted in the abdomen, is already approved in Europe and will be rolled out in a phased launch for the U.S. market. The pump is about 3 inches in diameter and about 1-inch thick, and i... |
| Jun 14, 2012 | Therapeutic hypothermia device to prevent brain injury gets a cool $1.5M | There are a few other companies innovating in this space, including Cryothermic Systems, Life Recovery Systems and BeneChill, a company that’s partnered with Physio-Control and has the CE Mark for a fast-evaporating liquid that cools the br... |
| May 25, 2012 | Cleveland Clinic patient becomes ‘ridiculously photogenic surgery girl’ | Nonetheless, Rachel apparently enjoyed the attention, posting: “I don’t get hit on all the time (maybe because I don’t like leaving my house if I don’t have to) and I feel pretty average. People have been saying so may nice things about me ... |
| Mar 28, 2012 | Stroke diagnosis company IschemiaCare planning clinical study | IschemiaCare’s blood test, called ISCDX, uses gene expression profiles to differentiate strokes that originate in the heart from those that originate in large blood vessels that lead to the brain.
Typically, a stroke’s cause is diagnosed by... |
| Dec 21, 2011 | The 50 best Cleveland Clinic doctors. Ever. | Ranking the greatest doctors over 90 years is like comparing NFL quarterbacks. Who was better: Peyton Manning or Johnny Unitas? How can one physician from the 1920s compare to another in today’s era of healthcare reform and big health syste... |
| Dec 9, 2011 | Stroke diagnosis startup IschemiaCare gets nearly $1M Ohio loan | IschemiaCare CEO Jeff June declined comment when reached by email.
In September, June said the company had closed on $800,000 of a $1.1 million series B round of investment he hoped to complete by the end of the year. IschemiaCare plans to ... |
| Nov 29, 2011 | NB Therapeutics raising $1 million to fund nail fungus therapy | Iontophoresis involves using electric currents to improve drug delivery through the skin and nails, a method the company says improves drug delivery since it can facilitate delivery of high concentrations of a medication in a single dose an... |
| Nov 15, 2011 | Forced productivity: Our new sweatshop | By Westby G. Fisher, MD, FACC
We have to ask ourselves, how are we going to take care of 32 million more patients in 2014 with a limited number of physicians to care for them? Better yet, how are we going to do this and save money doing it?... |
| Sep 28, 2011 | Thermalin Diabetes targets $8M series B investment, eyes clinical trials | Thermalin is targeting the end of 2012 to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration, which would likely enable the company to begin clinical trials in early 2013, Berenson said.
The compan... |
| Sep 15, 2011 | EndOclear using visual technology to help clean breathing tubes | EndOclear recently raised $500,000, according to federal regulatory filings.
The company was founded by Michigan cardiovascular surgeon Dr. Brad Vazales and is conducting studies to show efficacy of its technology, according to its website.... |
| Sep 1, 2011 | Stroke diagnosis firm IschemiaCare closes $800K of $1.1M investment | The company’s series B round was led by Cincinnati-based Queen City Angels and included company management and several individuals, June said.
IschemiaCare’s blood test, called ISCDX, would use gene expression profiles to differentiate stro... |
| Jun 5, 2011 | Is It Just Morning Sickness or Something More? | Most people associate pregnancy with morning sickness. While OB/GYN physicians consider a fair amount of nausea and vomiting as normal, severe and long-term symptoms can negatively impact the pregnancy and the mother’s quality of life. In f... |
| Dec 22, 2010 | Ischemia Care developing rapid stroke diagnostic | Don’t accuse molecular diagnostics startup Ischemia Care of thinking small.
The Oxford, Ohio-based company that was founded three years ago is hoping to be the first to market with a blood test to diagnose a stroke’s origin, the fourth-lead... |
| Oct 27, 2010 | University of Minnesota startup to attack vein disease in legs | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| Jun 30, 2010 | Vicept Therapeutics completes $16M Series A round | The funding round was led by California-based Vivo Ventures, California-based Sofinnova Ventures and Massachusetts-based Fidelity Biosciences, according to a statement from Vicept.
Vicept also plans to use the money to investigate other dru... |
| Apr 19, 2010 | When doctors are patients (and facing death) | The article also includes comments from Columbia University psychiatrist Robert Klitzman, MD who has written a book “When Doctors Become Patients”
After his own recovery, Klitzman wanted to understand the rare, dual perspective of physician... |
| Therapeutic hypothermia device to prevent brain injury gets a cool $1.5M | An under-wraps Silicon Valley startup that describes itself as “the cold cure for brain injury” has secured $1.5 million in financing.
NeuroSave Inc. CEO Seth Rodgers said the company still has a little ways to go before it can begin talkin... |
| University of Minnesota startup to attack vein disease in legs | When Mike Selzer first reviewed the work of University of Minnesota scientist Dr.Erik Cressman — a way to kill cancer cells in the liver using chemical-generated heat — the veteran medical device executive was impressed.
Cool technology, he... |
| Catabasis raising $20.4M; modulates multiple disease pathways for Duchenne muscular dystrophy, ALS | Multiple biological pathways go awry to cause disease. Cambridge startup Catabasis is developing a platform to simultaneously modulate multiple targets in a disease pathway, with a focus on diseases like Duchenne muscular dystrophy and ALS
... |
| Vicept Therapeutics completes $16M Series A round | Vicept Therapeutics Inc., a developer of topical treatments for skin disorders, has completed a $16 million Series A round of funding.
The Malvern, Penn. company plans to use the cash to fund Phase 1 and 2 development of V-101, the company’... |
| Drug developer with kidney disease treatment raises $13M ahead of IND filing | Complexa, a drug developer using synthetic fatty acids to treat chronic and acute kidney disease, has raised $13 million in a Series B financing round, according to a company statement. The new funding comes as it prepares to file an IND fo... |
| Subsidiary of Depuy Synthes receives FDA approval for implantable device that treats spasticity | Codman & Shurtleff Inc., part of the Depuy Synthes companies, announced Tuesday that it has received a premarket approval from the U.S. Food and Drug Administration to market a neuromodulation product that treats spasticity.
The MedStre... |
| Pediatric telemedicine could help screen preemies for eye disease, study finds | One of the interesting applications for pediatric telemedicine is ophthalmology, where specialists are spread thin or don’t exist at all in many communities. Similar to teleradiology, non-physicians could be used to screen images to spot po... |
| True North Therapeutics gets $40M new approach to autoimmune disease | Bay Area biotech True North Therapeutics just closed out a $40 million Series C for an exciting new approach to autoimmune disease – potentially shutting down the body’s ability to attack itself at the very beginning of the process. It’s ra... |
| Celiac disease immunotherapy that would replace a gluten-free diet begins clinical trials | A new, potential disease-altering drug treatment for celiac disease would eliminate the need for a gluten-free diet in certain patients with celiac disease.
Cambridge, Massachusetts drug company ImmusanT‘s drug, which has begun clinical tri... |
| Stroke diagnosis firm IschemiaCare closes $800K of $1.1M investment | A company that’s hoping to be the first to commercialize a blood test that can diagnose the cause of stroke has closed $800,000 of an anticipated $1.1 million series B round of investment.
Cincinnati-area-based IschemiaCare expects to close... |
| The 50 best Cleveland Clinic doctors. Ever. | The history of a hospital is written primarily by the actions of its doctors. From day one in 1921, Cleveland Clinic has always been about the doctors.
The elite health system has spent the last year celebrating its 90th birthday, making th... |
| How to engineer a social media attack on a hospital system | This video is NSFW.
Earlier this month, TriHealth employees faced a flu shot deadline. Get one or else, the Cincinnati health system said.
Apparently 150 people said no thanks, and the employer said buh-bye.
Since that initial announcement,... |
| A topical way to treat migraines with NSAIDs – and cut down on all those GI bleeds | There are only so many Advils a migraineur can pop before the ulcers and GI bleeds start setting in. They may be effective pain drugs, but NSAIDs are notorious for causing gastrointestinal distress – particularly when taken in the high dose... |
| Rinse-and-spit test kit company gets $2.3M to develop an early oral cancer screening | Oral cancers don’t get a lot of mainstream attention because they aren’t among the deadliest cancers by sheer numbers. They do, however, carry a surprisingly high mortality rate: between 40 and 50 percent of people diagnosed with an oral ca... |
| Docs on new concussion sensors, apps: They help but don’t solve key issues with diagnosis | Handheld diagnostic devices. Blood tests. Helmet sensors. Apps that evaluate everything from balance to speech patterns.
They’re all efforts being put forth by companies looking to cash in on the need for more sophisticated and less subject... |
| Supported by an $86 million round, first bio-artificial liver moves toward pivotal trials | The liver is an incredibly complex organ, critical for processing toxins and synthesizing 3,000 proteins and other molecules. It’s also one that’s in great demand by thousands of people needing a liver transplant each year.
But it’s also un... |
| Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication | A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idec’s Phase 3 trials last year: Though fast-tracked in 2009 for the i... |
| Allena Pharma’s kidney stone-preventing enzyme attracts $25M | Kidney stones are on the rise. One cause is a condition called hyperoxaluria – a potentially serious metabolic disorder that’s found in about 20-30 percent of patients with recurrent stones. It that lead to chronic kidney disease, end-stage... |
| Arcturus emerging as a strong player in RNA therapeutics space | With a fast-growing pipeline of siRNA and mRNA drugs, San Diego startup Arcturus Therapeutics is poised join the ranks of more established RNA-based drug companies like Alnylam and Moderna Therapeutics.
It’s welcome timing, as the market’s ... |
| Colon cancer prevention drug maker seeking $5 million ahead of pivotal trials | A company developing prevention drugs for people with elevated risk for colon cancer is raising $5 million ahead of two pivotal trials.
With its lead drug, Cancer Prevention Pharmaceuticals takes a two-pronged approach to preventing cancer ... |
| Cardiology-focused startup improving FFR emerges in Cleveland with $250K investment | A new Cleveland-based startup is innovating on diagnostic technology in cardiology with the hope of getting into a $1 billion (and growing) market dominated by St. Jude Medical and Volcano Corp.
Fractional flow reserve, or FFR, is a techniq... |
| Thermalin Diabetes targets $8M series B investment, eyes clinical trials | Next-generation insulin developer Thermalin Diabetes is targeting an $8 million series B round of investment that would fund the first in-human studies of its insulin analogs.
A successful clinical trial — though a long way off for the Clev... |
| Is It Just Morning Sickness or Something More? | Most people associate pregnancy with morning sickness. While OB/GYN physicians consider a fair amount of nausea and vomiting as normal, severe and long-term symptoms can negatively impact the pregnancy and the mother’s quality of life. In f... |
| Stroke diagnosis company IschemiaCare planning clinical study | A startup that’s developing a blood test to diagnose the cause of stroke is planning a clinical study that could pave the way to commercial sales of the test.
Cincinnati-based IschemiaCare plans to begin the study in the second half of this... |
| GeneSegues gets gov’t contract to develop a topical vaccine for Venezuelan encephalitis | Minneapolis vaccine developer GeneSegues Therapeutics has a new government contract to develop a DNA vaccine against Venezuelan equine encephalitis virus – an infectious disease that has the potential to be used as a bioweapon, the feds say... |
| Stem cell company Athersys expects more R&D spending, potential partnerships in 2013 | Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and ... |
| Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases | A one-year-old company using drug delivery to improve ophthalmic drugs is raising fresh capital to support trials of its microinjection platform.
Clearside Biomedical has raised $7.9 million and could continue raising up to $8.5 million, ac... |
| Vascular disease biopharma Aerpio nabs $27M for trials of diabetic macular edema drug | A biopharmaceutical company that spun out of Cincinnati-based Akebia Therapeutics just eight months ago has raised $27 million to support development and clinical trials of its drug for diabetic macular edema.
Novartis BioVentures led Aerpi... |
| When doctors are patients (and facing death) | In my office mail this morning I found my medical school classmate, Janet Cathey, looking back at me from the front of the last issue of the Journal of the Arkansas Medical Society. Her photo was linked to an article entitled “When Healers ... |
| Sophono raises $7M series B, rolls out new features of bone conduction hearing device | Company name: Sophono Inc.
Industry: medical devices.
Location: Boulder, Colorado.
Solution/product: The Alpha 1 is a U.S. Food and Drug Administration-cleared hearing device for patients with conductive hearing loss, mixed hearing loss and... |
| Where are they now? A look at Cleveland Clinic’s “top medical innovations” of the past | Last week, the Cleveland Clinic put out the 2013 version of its Top 10 Medical Innovations, an annual list of medical technologies that it expects to have the biggest impact on healthcare in 2013. At the top of the list was bariatric surger... |
